Carmel Pezaro
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Schmid S, De Giorgi U, Hansen A, Beer T, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman A, Le M, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Bianchini D, Chi K, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen M, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh W, Tsao C, Sartor O, Ledet E, Di Lorenzo G, Yip S, Gillessen S. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open 2020; 3:e2021692.
01.10.2020Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
01.10.2020JAMA Netw Open 2020; 3:e2021692
Schmid Sabine, De Giorgi Ugo, Hansen Aaron R, Beer Tomasz M, Lavaud Pernelle, Morales-Barrera Rafael, Tucci Marcello, Castro Elena, Karalis Kostas, Bergman Andries M, Le Mo Linh, Zürrer-Härdi Ursina, Pezaro Carmel, Suzuki Hiroyoshi, Zivi Andrea, Klingbiel Dirk, Schär Sämi, Bianchini Diletta, Chi Kim N, Omlin Aurelius, Higano Celestia, Sweeney Christopher, Martinez Chanza Nieves, Mehra Niven, Kuppen Malou C P, Beltran Himisha, Conteduca Vincenza, Vargas Pivato de Almeida Daniel, Cotait Maluf Fernando, Oh William K, Tsao Che-Kai, Sartor Oliver, Ledet Elisa, Di Lorenzo Giuseppe, Yip Steven M, Gillessen Silke
Living Longer and Better with Advanced Prostate Cancer
Mukherji D, Omlin A, Pezaro C. Living Longer and Better with Advanced Prostate Cancer. Eur Urol 2020; 78:358-359.
15.06.2020Living Longer and Better with Advanced Prostate Cancer
15.06.2020Eur Urol 2020; 78:358-359
Mukherji Deborah, Omlin Aurelius, Pezaro Carmel
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey
Lorente D, Hall E, IJzerman M, Terstappen L, Payne H, Mateo J, Perez R, Tunariu N, Bianchini D, Porta N, Kolinsky M, Rescigno P, Miranda M, Gilman A, Omlin A, Pezaro C, Mehra N, Ravi P, de Bono J. Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. Eur Urol Focus 2016; 4:235-244.
10.10.2016Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey
10.10.2016Eur Urol Focus 2016; 4:235-244
Lorente David, Hall Emma, IJzerman Maarten, Terstappen Leon, Payne Heather, Mateo Joaquin, Perez Raquel, Tunariu Nina, Bianchini Diletta, Porta Nuria, Kolinsky Michael, Rescigno Pasquale, Miranda Miguel, Gilman Alexa, Omlin Aurelius, Pezaro Carmel, Mehra Niven, Ravi Praful, de Bono Johann
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
Lorente D, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, Miranda S, Riisnaes R, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, de Bono J. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. Clin Genitourin Cancer 2016; 14:485-493.
05.05.2016Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
05.05.2016Clin Genitourin Cancer 2016; 14:485-493
Lorente David, Crespo Mateus, Flohr Penny, Mateo Joaquin, Altavilla Amelia, Ferraldeschi Roberta, Bianchini Diletta, Attard Gerhardt, Tunariu Nina, Miranda Susana, Riisnaes Ruth, Omlin Aurelius, Zafeiriou Zafeiris, Nava-Rodrigues Daniel, Pérez-López Raquel, Pezaro Carmel, Mehra Niven, Sheridan Elizabeth, Figueiredo Ines, de Bono Johann
PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
Ferraldeschi R, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, Altavilla A, Mateo J, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, de Bono J. PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. Eur Urol 2014
04.11.2014PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
04.11.2014Eur Urol 2014
Ferraldeschi Roberta, Sideris Spyridon, Bianchini Diletta, Grist Emily, Thway Khin, Perez Lopez Raquel, Tunariu Nina, Parker Chris, Dearnaley David, Reid Alison, Attard Gerhardt, Altavilla Amelia, Mateo Joaquin, Nava Rodrigues Daniel, Riisnaes Ruth, Miranda Susana, Figueiredo Ines, Rescigno Pasquale, Ravi Praful, Pezaro Carmel, Omlin Aurelius, Lorente David, Zafeiriou Zafeiris, de Bono Johann
Tumor clone dynamics in lethal prostate cancer
Carreira S, Demichelis F, S de Bono J, Tunariu N, Flohr P, Rodrigues D, Omlin A, Pezaro C, Frenel J, Lorente D, Prandi D, Miranda S, Ferraldeschi R, Grist E, Goodall J, Romanel A, Attard G. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014; 6:254ra125.
17.09.2014Tumor clone dynamics in lethal prostate cancer
17.09.2014Sci Transl Med 2014; 6:254ra125
Carreira Suzanne, Demichelis Francesca, S de Bono Johann, Tunariu Nina, Flohr Penelope, Rodrigues Daniel Nava, Omlin Aurelius, Pezaro Carmel, Frenel Jean-Sebastien, Lorente David, Prandi Davide, Miranda Susana, Ferraldeschi Roberta, Grist Emily, Goodall Jane, Romanel Alessandro, Attard Gerhardt
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
Mukherji D, Omlin A, Pezaro C, Shamseddine A, de Bono J. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev 2014; 33:555-66.
01.09.2014Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
01.09.2014Cancer Metastasis Rev 2014; 33:555-66
Mukherji Deborah, Omlin Aurelius, Pezaro Carmel, Shamseddine Ali, de Bono Johann
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
Templeton A, Tannock I, de Bono J, Attard G, Vera-Badillo F, Leibowitz-Amit R, McNamara M, Omlin A, Pezaro C, Amir E. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014; 120:3346-52.
03.07.2014Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio
03.07.2014Cancer 2014; 120:3346-52
Templeton Arnoud, Tannock Ian F, de Bono Johann S, Attard Gerhardt, Vera-Badillo Francisco E, Leibowitz-Amit Raya, McNamara Mairead G, Omlin Aurelius, Pezaro Carmel, Amir Eitan
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014; 6:3-14.
01.02.2014Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
01.02.2014Ther Adv Urol 2014; 6:3-14
Omlin Aurelius, Pezaro Carmel, Gillessen Sommer Silke
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
Lorente D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Bianchini D, de Bono J. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. Eur J Cancer 2014; 50:1042-3.
13.01.2014Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
13.01.2014Eur J Cancer 2014; 50:1042-3
Lorente David, Chowdhury Simon, Attard Gerhardt, Zivi Andrea, Ferraldeschi Roberta, Pezaro Carmel, Omlin Aurelius, Rodriguez-Vida Alejo, Bianchini Diletta, de Bono Johann S
Management of patients with castration-resistant disease
Pezaro C, Omlin A, Lorente D, de Bono J. Management of patients with castration-resistant disease. Hematol Oncol Clin North Am 2013; 27:1243-60, ix.
20.09.2013Management of patients with castration-resistant disease
20.09.2013Hematol Oncol Clin North Am 2013; 27:1243-60, ix
Pezaro Carmel, Omlin Aurelius, Lorente David, de Bono Johann
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
Omlin A, Attard G, Parker C, Thompson E, Maier G, Ferraldeschi R, Olmos D, Bianchini D, Sandhu S, Mulick Cassidy A, Mukherji D, Pezaro C, de Bono J. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013; 64:300-6.
04.01.2013Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms
04.01.2013Eur Urol 2013; 64:300-6
Omlin Aurelius, Attard Gerhardt, Parker Chris, Thompson Emilda, Maier Gal, Ferraldeschi Roberta, Olmos David, Bianchini Diletta, Sandhu Shahneen, Mulick Cassidy Amy, Mukherji Deborah, Pezaro Carmel, de Bono Johann